CTCA Western clinical research director authors five innovative studies presented at ASCO

Dr. Glen Weiss is a Translational Physician Scientist (TPS) with a joint appointment at TGen and Cancer Treatment Centers of America. He is board certified in internal medicine and medical oncology. He is currently Co-Head of the Lung Cancer Unit and Clinical Associate Professor at TGen, Director of Clinical Research at Cancer Treatment Centers of America, and holds a Clinical Assistant Professor of Medicine appointment at the University of Arizona College of Medicine-Phoenix.Continue reading

VisionGate Hires Renowned Chief Medical Officer Dr. Javier Zulueta

PHOENIX, Ariz. (June 2, 2016) – VisionGate, Inc. today announced the appointment of Dr. Javier Zulueta as its Chief Medical Officer. A world-renowned pulmonologist, professor and 16-year Director of Pulmonary Service at the University Clinic of Navarra, the teaching hospital of Spain’s University of Navarra School of Medicine, Dr. Zulueta will provide expert counsel and oversight of VisionGate’s clinical collaborations and associated clinical trials in lung cancer early detection and chemoprevention therapy.Continue reading

Explore the Neuron Forest and Discover Arizona Opportunities in the Arizona Pavilion at BIO 2016

Rising above the Arizona Pavilion at the BIO International Convention, you will find picture-postcard vistas of Arizona’s natural wonders.

Inside the Arizona Pavilion, visitors have the opportunity to explore new vistas as they take a virtual reality journey inside the human brain, meet with award winning life science innovators, and learn about a wide range of Arizona opportunities.Continue reading

The biopharmaceutical sector had nearly $10B economic impact in Arizona

PBJ small

Republished with permission from the Phoenix Business Journal. All Rights Reserved  Source

The biopharmaceutical industry is a major contributor to the U.S. economy, and also has a growing presence in Arizona, according to a new report released by TEConomy Partners LLC.

 

Since 2000, members companies of PhRMA have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.Continue reading